

Higher Elastase Activity Associated with Lower IL-18 in GCF from Juvenile Systemic Lupus Patients

Carlos Marcelo S. Figueredo^{a,b}/Alessandra Areas^a/Flávio R.Sztajnbok^c/Vivian Miceli^a/Letícia A. Miranda^b/Ricardo G. Fischer^a/Anders Gustafsson^b

Purpose: Theour aim was to evaluate the expression of interleukin-18 (IL-18) and, interleukin-1-beta (IL-1b,) and the amount of elastase activity in gingival crevicular fluid (GCF) from inflamed gingival sites in patients with juvenile systemic lupus erythematosus (JSLE), and compare these to the expression in GCF from inflamed sites in generally healthy controls. In addition, we related the local inflammation in periodontal tissues was related to systemic inflammation by the assessment of IL-18 levels in plasma.

Materials and Methods: GCF from 16 patients with JSLE and 14 controls were collected using a washing device. Elastase activity was measured with a specific substrate, and IL-18 and IL-1 β were measured by ELISA.

Results: The percentage of visible plaque index, gingival bleeding index and attachment level were similar in JSLE and controls, while the percentage of probing depth greater or equal to 3 mm was significantly higher in the controls. The total amount of IL-1 β and IL-18 in GCF were significantly decreased in JSLE, while the total amount and the percentage of free elastase activity were significantly higher in JSLE when compared with the controls. The plasma levels of IL-18 and the Eerythrocyte Ssed-imentation Rrate were significantly higher in JSLE patients.

Conclusion: We found more active elastase in GCF from inflamed sites in JSLE patients even in the presence of significantly lower levels of IL-18 and IL-1 β . The increased elastase activity suggests a hyperactivity of neutrophils in JSLE, possibly generated by a priming effect caused by the higher plasma levels of IL-18 found in these JSLE patients.

Key words: elastase, IL-18, IL1-b, juvenile systemic lupus erythematosus, periodontitis.

Oral Health Prev Dent 2008;1:xxx-xxx.

Submitted for publication: xxxxxxxx; accepted for publication: xxxxxxxx.

Systemic Lupus Erythematosus (SLE) is a chronic auto-immune disease, characterised by immune responses directed to a great number of self antigens that mostly affects women in their second or third decade of life. SLE can affect various parts of the body, including joints, skin, kidney, heart, lungs, blood ves-

sels and the brain (for review see Danchenko et al, 2006). The incidence of juvenile SLE (JSLE) is estimated between 6–20 cases per 100,000 children, and mainly occurs in girls and in children of non-Caucasian origin (Hoschberg 1997, Stichweh et al, 2004). The pathoaetiology of this chronic disease remains unclear, but genetic, immunological and environmental factors have all been implicated. Patients with SLE have been shown to have elevated plasma interleukin-18 (IL-18) concentrations (Tso et al, 2006).

IL-18, formerly called interferon (IFN)- γ -inducing factor, is a pro-inflammatory cytokine related to the IL-1 family that is produced by Kupffer cells, activated macrophages, keratinocytes, intestinal epithelial cells, osteoblasts and adrenal cortex cells (Dinarello 1999). IL-18 is produced as a 24 kDa inactive precursor and is cleaved by the IL-1, converting enzyme (ICE, caspase-1) to generate a biologically active mature 18 kDa moiety (Ghayur et al, 1997). It plays an important

^a Department of Periodontology, Rio de Janeiro State University - UERJ, Rio de Janeiro, Brazil

^b Division of Periodontology, Institute of Odontology, Karolinska Institutet, Huddinge, Sweden

^c Pediatric Rheumatologic Unit, Adolescent Hhealth Care Unit, Rio de Janeiro State University - UERJ, Rio de Janeiro, Brazil

Reprint requests: Carlos Marcelo da Silva Figueredo, Faculdade de Odontologia - Secretaria de Pós-graduação e Pesquisa, Av. 28 de setembro, 157, Vila Isabel, Rio de Janeiro, RJ, Brasil, CEP: 20551-030. Tel: + 55 21 25876255. Fax: + 55 21 25876255. E-mail: cm-figueredo@hotmail.com

role in innate immunity and it has been shown to induce T-helper cells type I (Th1) and Th2 cytokines, such as IL-4, IL-5, IL-10 and IL-13 (Hoshino et al, 1999). The primary functions of IL-18 include the induction of IFN- γ and tumor necrosis factor α (TNF- α) in T cells and natural killer (NK) cells (Tanaka et al, 2001), and the up-regulation of Th1 cytokines including IL-2, granulocyte macrophage colony stimulating factor (GM-CSF) and IFN- γ (Dinarello 1999).

Human neutrophils, both in circulation and in the tissues, constitutively express the IL-18 receptor (IL-18R) (Leung et al, 2001). IL-18 induces cytokine and chemokine release from neutrophils, induces granule release and enhances the respiratory burst (Leung et al, 2001). The capacity to release cytokines and chemokines was significantly enhanced in neutrophils derived from rheumatoid arthritis synovial fluid, indicating a differential response to IL-18 dependent upon prior neutrophil activation *in vivo*.

Activated neutrophils release elastase, a serine protease, which degrades elastin and several other functionally and structurally important proteins in the periodontium, including collagen, proteoglycans and basement membrane components (Janoff, 1985). Several studies have shown increased activity of this protease in gingival crevicular fluid (GCF) from sites of periodontitis (Overall et al, 1987; Gustafsson et al, 1994; Ingman et al, 1996; Meyer et al, 1997; Figueredo and Gustafsson 1998). Elastase is released in an active form but is normally rapidly inhibited by the protease inhibitors α -1-antitrypsin (A1AT) and α -2-macroglobulin (A2MG). Some studies have indicated that this inhibition is less effective in inflamed periodontal tissues from patients with periodontitis, thereby allowing the elastase to remain active for a longer period of time.

IL-1 β a potent pro-inflammatory cytokine, has been considered a pivotal signalling substance involved in the up-regulation of matrix metalloproteinases and down-regulation of tissue inhibitors (Page et al, 1997 for review). Earlier studies have shown high levels of IL-1, in sites with periodontitis (Figueredo et al, 1999; Orozco et al, 2006). The role of IL-18 in periodontal disease has been less well studied. Orozco et al (2006) showed increased levels of GCF from inflamed sites of periodontitis patients.

Therefore, the aim was to evaluate the expression of IL-18 and IL-1, and the amount of elastase activity in GCF from inflamed gingival sites in patients with JSLE, and compare these to the expression in GCF from inflamed sites in generally healthy controls. In addition, the local inflammation in periodontal tissues was related to systemic inflammation by the assessment of IL-18 levels in plasma.

MATERIALS AND METHODS

Participants

The patient group comprised 16 adolescents (mean age: 15.6, SD \pm 2.7 years) who were attending the Pediatric Rheumatology Clinic (NESA), Rio de Janeiro State University (UERJ), Rio de Janeiro, Brazil. Diagnosis of the patients' SLE had previously been made by the same physician, in accordance with the classification of the American College of Rheumatology (Hoschberg, 1997). The median duration of disease was 4 years (range 1 to 10 years). Thirteen patients were taking medication. Fourteen individuals (mean age: 15.5, SD \pm 1.5 years) with no signs of ongoing infections or inflammatory diseases were selected as controls. These persons were recruited among those visiting the clinic for an annual medical check up. The Ethics Committee of Pedro Ernesto University Hospital (UERJ, Rio de Janeiro, Brazil) and the Regional Ethics Committee in Stockholm, Sweden approved this study. All volunteers and parents/guardians gave written consent to participate. The patients answered a questionnaire concerning their personal data.

Clinical examination

Periodontal and rheumatological clinical examinations were performed. All tooth surfaces, except for third molars, of the selected patients were examined with a type Williams probe (PCP10 Color Coded Probe, - Hu-Friedy Co., Chicago, EUAUSA), by the same calibrated examiner. The variables registered were percentage of visible plaque index (VPI) and gingival bleeding index (GBI) (Ainamo & Bay 1975), pocket probing depth (PD) and clinical attachment level (AL).

Clinical evaluation of rheumatological findings

The rheumatologic evaluation comprised a clinical examination and the measurement of the disease activity through the Global Medical Evaluation (GME) in an analogue visual scale (ranged from inactive to severe). The Systemic Lupus International Collaborating Clinics (SLICC) evaluation and the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) were used to measure SLE damage and activity, respectively. All evaluations were performed by the same paediatric rheumatologist.

The JSLE patients were sub-divided according to the disease activity. A patient with a SLEDAI score differ-

ent from zero was considered to have active disease. Thirteen of the 16 participating patients took immunosuppressant drugs, prednisone, chloroquine and azathioprine, and five of them also took non-steroidal anti-inflammatory drugs (NASIDs).

GCF sampling method

Samples were taken from five to six deep pockets or the most inflamed sites. GCF was collected with an intracrevicular washing device modified from Salonen and Paunio (1991). The sites to be sampled were isolated with cotton rolls and dried gently with an air syringe. Supragingival plaque was carefully removed before sampling. Each pocket selected was washed five times with 5 µl of phosphate buffer saline (PBS) during continuous aspiration. The samples from the same type of site in each person were pooled, diluted with PBS to a volume of 1 ml and immediately centrifuged at 3000 g for 10 min. The supernatant was collected and frozen at 70°C, pending analysis.

For the blood samples, Twenty milliliters a total of 20 ml of venous peripheral blood were collected from each patient and control subject and stored in heparinized tubes.

Elastase activity

The granulocyte elastase substrate S-2484 (L-pyroglyutamyl-L-prolyl-L-valine-p-nitroaniline, MW 445.5 Da, Heamatochrome Diagnostica AB, Mölndal, Sweden) was dissolved in dimethyl sulfoxide to 8 mmol/l and the working solution was made to 2 mmol/l by dilution in PBS. The alkaline phosphatase substrate, p-nitrophenol phosphate (Janssen Chimica, Geel, Belgium), was diluted to 2.7 mmol/l in diethanolamine buffer, pH 10.0. A total of 100 µl of sample was mixed with 67 µl of substrate in a 96-well microtitre plate (Nunc Maxisorb, Nunc, Roskilde, Denmark). The mixture was incubated at 37°C and the absorbency at 405 nm was read after 2 h in a spectrophotometer (Millenia Kinetic Analyzer, Diagnostic Product Corporation, Los Angeles, CA, USA). The elastase activity was expressed in an arbitrary unit mAbs. To inhibit elastase activity, 10 µl of 0.1% A1AT was added to 90 µl of sample and incubated with agitation for 15 min at room temperature. After inhibition, the samples were tested for elastase activity, as described above. The elastase activity inhibited by A1AT was regarded as deriving from free elastase and the remaining activity as deriving from elastase bound to A2MG.

Immunological assays

In the gingival fluid, IL-1, was measured using enzyme-linked immunosorbant assay (ELISA), as reported earlier (Figueredo et al, 1999). A monoclonal antibody against IL-1, (MAB 601, R & D Systems, Minneapolis, MN, USA) diluted 1:125 in carbonate buffer was coated onto microtitre plates (Nunc Maxisorb, Nunc a/s, Roskilde, Denmark) at 4°C overnight. Samples and standards were diluted in PBS, pH 7.4. The microtitre plates were washed with PBS containing 0.05% polyoxyethylene sorbitan monolaurate (Tween® 20, Sigma Chemical, St Louis, MO, USA). After washing with PBS/Tween (4 times with 300 µl) the plates were blocked with 1% human serum albumin (HSA) for 1 hour at room temperature. The samples were washed as above and 100 µl of standard (2 pg/ml to 200 pg/ml) and undiluted samples were added respectively. The plates were incubated at 37°C for 45 min followed by washing. The detection antibody (BAF 201, R & D Systems, Minneapolis, MN, USA) was diluted 1:250 in PBS and incubated for 45 min. After washing, streptavidin diluted 1:200 was added to the plates and incubated further at 37°C for 20 min. The plates were once again washed and the undiluted substrate was added (TMB, Sigma Chemical, St. Louis, MO, USA). The reaction was stopped with 1M H2SO4 after 15 minutes and the absorbency was read at 450 nm in a spectrophotometer.

IL-18 was measured in GCF and in plasma with commercially available ELISA kits (IL-18, MBL, Nagoya, Japan), according to the manufacturer instructions. Total amounts of IL-1, and IL-18 were expressed as pg/ml.

Immunological assays

In the gingival fluid, IL-1b, was measured using enzyme-linked immunosorbant assay (ELISA), as reported earlier (Figueredo et al, 1999). Shortly, a monoclonal antibody against IL-1β (MAB 601, R & D Systems, Minneapolis, MN, USA) diluted 1:125 in carbonate buffer was coated onto microtitre plates (Nunc Maxisorb, Nunc a/s, Roskilde, Denmark) at 4°C overnight. Samples and standards were diluted in PBS, pH 7.4. The microtitre plates were washed with PBS + containing 0.05% polyoxyethylene sorbitan monolaurate (Tween® 20, Sigma Chemical, St Louis, MO, USA). After washing with PBS / Tween (4 times with 300 µl) the plates were blocked with 1% human serum albumin (HSA) for 1 hour at room temperature. The samples were washed as above and 100 µl of standard (2 pg/mL ml to 200 pg/mLml) and undiluted

Table 1 Percentual mean (\pm standard deviation) of visible plaque index (VPI), gingival bleeding index (GBI), sites with pocket depth (PD) \geq 3 mm and sites with proximal attachment loss (AL) \geq 2 mm in JSLE and control groups, and in the active and inactive subgroups.

	VPI	GBI	PD	AL
JSLE n = 16	33 (\pm 19)	33.2 (\pm 16)	17 (\pm 16)	0.2 (\pm 0,6)
Control n = 14	35 (\pm 18)	39 (\pm 13)	30 (\pm 18) *	0.2 (\pm 0,3)
JSLE active n = 10	41 (\pm 19) ***	39 (\pm 16) **	20 (\pm 16)	0.2 (\pm 0.5)
JSLE inactive n = 6	19 (\pm 9)	23 (\pm 11)	13 (\pm 16)	0.1 (\pm 0.3)

JSLE: juvenile systemic lupus erythematosus; AL: presence of at least 1 proximal site with AL \geq 2 mm.
 * JSLE versus control, Mann-Whitney test, $p < 0.05$; ** JSLE active versus JSLE inactive, Mann-Whitney test, $p < 0.05$; *** JSLE active versus JSLE inactive, Mann-Whitney test, $p < 0.01$.

samples were added respectively. The plates were incubated at 37°C for 45 min followed by washing. The detection antibody (BAF 201, R & D Systems, Minneapolis, MN, USA) was diluted 1:250 in PBS and incubated for 45 min. After washing, streptavidin, diluted 1:200 was added to the plates and incubated further at 37°C for 20 min. The plates were once again washed and the undiluted substrate was added (TMB, Sigma Chemical, St. Louis, MO, USA). The reaction was stopped with 1M H₂SO₄ after 15 minutes and the absorbency was read at 450 nm in a spectrophotometer.

IL-18 was measured in GCF and in plasma with a commercially available ELISA kits (IL-18, MBL, Nagoya, Japan), according to the manufacturer instructions. Total amounts of IL-1 β , and IL-18 were expressed as pg/mL.

Statistical analysis

The unit of analysis was the individual and the significance was set at 5%. Mann-Whitney and Spearman's correlation were applied as indicated in the text/tables. SPSS 8.0 software was used to analyze the data.

RESULTS RESULTS

JSLE versus Controls

The percentage of visible plaque index VPI, gingival bleeding index GBI and attachment level AL were similar

in JSLE and controls while the percentage of probing depth PD greater or equal to 3 mm was higher in the controls ($p = 0.03$,) (Table 1).

The total amount of IL-1 β and IL-18 in GCF were significantly decreased in JSLE when compared to controls ($p = 0.05$ and 0.02 , respectively), while the total amount and the percentage of free elastase activity were significantly higher in JSLE when compared with controls ($p = 0.03$ and 0.001 , respectively, y) (Table 2).

The plasma levels of IL-18 and erythrocyte sedimentation rate (ERS) were significantly higher in JSLE patients ($p = 0.04$ and 0.03 , respectively,) (Table 2). The SLEDAI median was 48 (range from 0 to 36) and the SLICC median was 0 (range from 0 to 8). IL-18 in plasma did not correlate with ERS or with the rheumatological evaluation using the SLEDAI scale.

Active versus inactive JSLE

The percentage of visible plaque index and gingival bleeding index were higher in active compared with inactive JSLE patients, while the percentage of probing depth (PD) greater or equal to 3 mm, and attachment level (AL) greater or equal to 2mm was similar within between them (Table 1).

The total amount of IL-1 β , and IL-18, and the total amount and the percentage of free elastase activity in GCF were similar in active and inactive JSLE patients. The same results were observed with the plasma levels of IL-18 and ERS (Table 2).

Table 2 Mean concentration of Inflammatory markers in GCF and plasma (\pm standard deviation) in JSLE and control groups, and JSLE active and inactive subgroups.

	GCF biomarkers			Plasma biomarkers			
	Total elastase (mAbs)	E-2MG (mAbs)	Free elastase	% Free elastase	IL-1, (pg/mL)	IL-18 (pg/mL)	ERS (mm/h)
JSLE n = 16	630 (\pm 598)	125 (\pm 72)	506 (\pm 540)	62 (\pm 30)	18 (\pm 17)	453 (\pm 302)	23 (\pm 16)
Control n = 14	474 (\pm 486)	331 (\pm 157)	180 (\pm 381)	19 (\pm 23)	30 (\pm 19)	315 (\pm 61)	8 (\pm 12)
P	NS	0.001	0.03	0.001	0.05	0.04	0.03
JSLE active n = 10	859 (\pm 642)	142 (\pm 84)	717 (\pm 569)	72 (\pm 27)	21 (\pm 21)	496 (\pm 364)	22 (\pm 18)
JSLE inactive n = 6	250 (\pm 233)	97 (\pm 33)	154 (\pm 236)	46 (\pm 20)	14 (10)	375 (\pm 86)	25 (\pm 12)
p	0.05	NS	0.07	NS	NS	NS	NS

E- α 2MG: elastase plus α -2 macroglobulin. ESR: erythrocyte sedimentation rate. NS: non significant, Mann-Whitney test, $p \geq 0.05$.

DISCUSSION

The present study showed more unbound elastase, corresponding to still active elastase in the GCF samples from inflamed gingival sites in patients with JSLE, when compared with inflamed sites in the control patients. Elastase activity in GCF samples has been convincingly associated with inflammation and tissue destruction in periodontal disease Figueredo and Gustafsson, 1998; Loos and Tjoa, 2005. Armitage et al, 1994 showed that sites with high levels of elastase are at a significantly greater risk for progressive bone loss as assessed by digital subtraction radiography. Elastase is released from the cells in an active form but under normal circumstances the body has effective ways of inhibiting this potentially damaging enzyme. Remaining active elastase in the gingival pocket could be due to hyperactive neutrophils generating large amounts of reactive oxygen species, which can inactivate the most abundant protease inhibitor in A1AT. This increased concentration of active elastase in the gingival pocket could indicate that patients with JSLE are at a greater risk of tissue degradation and in the long- term clinical attachment loss.

In contrast to elastase, lower levels of IL-18 and IL-1 β were observed in the patient group. Several studies have shown that IL-1 β is increased in inflamed periodontal tissues as compared to controls (Figueredo et al, 1999; Faizuddin et al, 2003; Hou et al, 2003, Faizuddin et al, 2003). Increased levels of IL-1, have been strongly associated with high neutrophil activity (Drugarin et al, 1998; Figueredo et al, 2000), whereas the role of IL-18 in periodontal disease has been less studied. Johnson and Serio (2005) evaluated IL-18 in gingival biopsies and observed higher concentrations in deeper pockets (\geq 6mm). The lower levels of IL-1 β and IL-18 in GCF from JSLE patients could result from the use of various different anti-inflammatory drugs. The JSLE patients were prescribed several medications according to their clinical manifestation of the disease. Some of these medications, such as prednisone, chloroquine and azathioprine have an immunosuppressive effect (for a review, see Barrera et al, 1996). Prednisone and azathioprine have been shown to lower the concentration of IL-1b, in a mouse lipopolysaccharide (LPS) induced inflammation model (Brustolim et al, 2006). Jang et al, (2006) showed that chloroquine-mediated inhibition of TNF- α , IL-1 β and IL-6 synthesis occurred through different modes in LPS-stimulated human monocytes/macrophages. Wozniacka et al, (2006) showed that after three - months of chloroquine therapy, the mean level of IL-6, IL-18 and TNF- α decreased significantly in the serum.

Taken together, it is reasonable to believe propose that in the current study, the local production of IL-1 β and IL-18 in the gingiva was affected by the systemic use of the anti-inflammatory drugs mentioned above.

The plasma IL-18 concentration, in contrast to that in GCF, was higher in JSLE than in controls. This might indicate that the plasma IL-18 has an effect on local neutrophil activity. This hypothesis is supported by Wyman et al, (2002) who found that IL-18, even at physiological concentrations, is an effective neutrophil priming agent. Hewins et al, (2006) also reported that IL-18 is likely to be important for neutrophil recruitment and priming in anti-neutrophil cytoplasmic autoantibody-associated systemic vasculitis. Priming has been defined as the cells are 'ready to go' but awaiting further stimulus before the oxidase response is elicited. For example, only the activated cells show oxidase activity, but if the primed cell also receives an activating stimulus, the ensuing oxidase activity is greater than that in non-primed, activated cells (Hallet and Lloyds, 1995). Greater chemotaxis and degranulation have also been demonstrated when neutrophils are primed with cytokines, such as TNF- α (Bajaj et al, 1992), IL-1 β (Brandolini et al, 1997) and IL-18 (Hewins et al, 2006). Therefore, we it is hypothetized that the higher neutrophil activity found in JSLE might be related to some kind of pre-activation caused by the higher levels of IL-18 in the plasma.

The current study was not able to show any changes in the attachment level between JSLE and controls, but control patients did show significantly more pocket probing depths greater or equal to 3mm. This finding is in agreement with Mutlu et al. (1993) who reported significantly lower periodontal probing depths in the patient group compared with the healthy controls. A possible explanation for this could be the use of disease-modifying drugs among the SLE patients. Only a few other studies reported the periodontal conditions in of SLE patients, and to date no studies have properly described the periodontal conditions in JSLE. Nagler et al, (1999) published a case report of an 18-year-old female with SLE and generalised periodontal involvement. The patient had multiple gingival recessions but no periodontal pockets or gingival bleeding. Two other cases of SLE patients with either periodontitis (Vogel, 1981) or severe gingivitis (Gonzalez-Crespo and Gornez-Reivo, 1995) have been reported.

In conclusion, we the present study reports higher levels of active elastase in GCF from inflamed sites in JSLE patients in spite of significantly lower levels of IL-18 and IL-1 β suggesting a greater risk of tissue degradation and periodontal attachment loss compared with healthy juvenile controls. The local hyperactivity of

neutrophils in JSLE could be somehow generated by the priming effect caused by the higher plasma levels of IL-18 found in these JSLE patients.

REFERENCES

1. Ainamo J, Bay I. Problems and proposals for recording gingivitis and plaque. *Int Dent J* 1975; 25: 229-235.
2. Armitage GC, Jeffcoat MK, Chadwick DE, Taggart EJJ, Numabe Y, Landis, JR., Weaver SL & Sharp TJet al. Longitudinal evaluation of elastase as a marker for the progression of periodontitis. *J Periodontol* 1994; 65: 120-128.
3. Bajaj MS, Kew RR, Webster RO, Hyers TM. Priming of human neutrophil functions by tumor necrosis factor: enhancement of superoxide anion generation, degranulation, and chemotaxis to chemoattractants C5a and F-Met-Leu-Phe. *Inflammation* 1992; 16: 241-250.
4. Barrera P, Boerbooms AM, van de Putte LB, van der Meer JW. Effects of antirheumatic agents on cytokines. *Semin Arthritis Rheum* 1996; 25: 234-253.
5. Brandolini L, Sergi R, Caselli G, Boraschi D, Locati M, Sozzani, S, Bertini, R. Interleukin-1 beta primes interleukin-8-stimulated chemotaxis and elastase release in human neutrophils via its type I receptor. *Eur Cytokine Netw* 1997; 8: 173-178.
6. Brustolim D, Ribeiro-dos-Santos R, Kast RE, Altschuler EL, Soares MB. A new chapter opens in anti-inflammatory treatments: the antidepressant bupropion lowers production of tumor necrosis factor-alpha and interferon-gamma in mice. *Int Immunopharmacol* 2006; 6: 903-907.
7. Danchenko, N., Satia, J. A., & Anthony, M. S. (2006). Epidemiology of systemic lupus erythematosus: a comparison of worldwide disease burden. *Lupus*, 2006;15, 308-318.
8. Dinarello CA. IL-18: a T-inducing proinflammatory cytokine and new member of the IL-1 family. *J Allergy Clin Immunol* 1999; 103: 11-24.
9. Drugarin D, Onisei D, Koreck A, Negru S, Drugarin M. Proinflammatory cytokines production and PMN-elastase release from activated PMN cells in the periodontal disease. *Roum Arch Microbiol Immunol* 1998; 57: 295-307.
10. Faizuddin M, Bharathi SH, Rohini NV. Estimation of interleukin-1beta levels in the gingival crevicular fluid in health and in inflammatory periodontal disease. *J Periodontal Res* 2003; 38: 111-114.
11. Figueredo CM, Gustafsson A. Protease activity in gingival crevicular fluid: presence of free protease. *J Clin Periodontol* 1998; 25: 306-310.
12. Figueredo CM, Ribeiro MS, Fischer RG, Gustafsson A. Increased interleukin-1beta concentration in gingival crevicular fluid as a characteristic of periodontitis. *J Periodontol* 1999; 70: 1457-1463.
13. Figueredo CM, Gustafsson A., Asman B, Bergstrom K. () Expression of intracellular elastase activity in peripheral neutrophils from patients with adult periodontitis. *J Clin Periodontol* 2000; 27: 572-577.
14. Ghayur T, Banerjee S, Hugunin M, Butler D, Herzog L, Carter A., Quintal L, Sekut L, Talanian R, Paskind M, Wong W, Kamen R, Tracey D, Allen, Het al. Caspase-1 processes IFN-gamma-inducing factor and regulates LPS-induced IFN-gamma production. *Nature* 1997; 386: 619-623.
15. Gonzalez-Crespo MR, Gornez-Reivo JG. Invasive aspergillobrin in systemic lupus erythematosus. *Semin Arthritis Rheum* 1995; 24: 304-314.

16. Gustafsson A, Asman B, Bergstrom K. Elastase and lactoferrin in gingival crevicular fluid: possible indicators of a granulocyte-associated specific host response. *J Periodontol Res* 1994; 29: 276-282.
17. Hallett MB, Lloyds D. Neutrophil priming: the cellular signals that say 'amber' but not 'green'. *Immunol Today* 1995; 16: 264-268.
18. Hewins P, Morgan MD, Holden N, Neil D, Williams JM, Savage CO, Harper L. IL-18 is upregulated in the kidney and primes neutrophil responsiveness in ANCA-associated vasculitis. *Kidney Int* 2006; 69: 605-615.
19. Hoshberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. *Arthritis Rheum* 1997; 4: 83-85.
20. Hoshino K, Kashiwamura S, Kuribayashi K, Kodama T, Tsujimura T, Nakanishi K, Matsuyama T, Takeda K, Akira S et al. The absence of interleukin 1 receptor-related T1/ST2 does not affect T helper cell type 2 development and its effector function. *J Exp Med* 1999; 190: 1541-1548.
21. Hou LT, Liu CM, Liu BY, Lin SJ, Liao CS, Rossomando EF. Interleukin-1, clinical parameters and matched cellular-histopathologic changes of biopsed gingival tissues from periodontitis patients. *J Periodontol Res* 2003; 38: 247-254.
22. Ingman T, Tervahartiala T, Ding Y, Tschesche H, Haerian A, Kinane DF, Konttinen YT, Sorsa T et al. Matrix metalloproteinases and their inhibitors in gingival crevicular fluid and saliva of periodontitis patients. *J Clin Periodontol* 1996; 23: 1127-1132.
23. Jang CH, Choi JH, Byun MS, Jue DM. Chloroquine inhibits production of TNF-alpha, IL-1beta and IL-6 from lipopolysaccharide-stimulated human monocytes/macrophages by different modes. *Rheumatology (Oxford)* 2006; 45: 703-710.
24. Janoff A. Elastase in tissue injury. *Annu Rev Med* 1985; 36: 207-216.
25. Johnson RB, Serio FG. Interleukin-18 concentrations and the pathogenesis of periodontal disease. *J Periodontol* 2005; 76: 785-790.
26. Leung BP, Culshaw S, Gracie JA, Hunter D, Canetti CA, Campbell C, Cunha F, Liew FY, McInnes IB et al. A role for IL-18 in neutrophil activation. *J Immunol* 2001; 167: 2879-2886.
27. Loos BG, Tjoa S. Host-derived diagnostic markers for periodontitis: do they exist in gingival crevice fluid? *Periodontol* 2000 2005; 39: 53-72.
28. Mercado FB, Marshall RI, Klestov AC, Bartold PM. Relationship between rheumatoid arthritis and periodontitis. *J Periodontol* 2001; 72: 779-787.
29. Meyer J, Guessous F, Huynh C, Godeau G, Hornebeck W, Giroud JP, Roch-Arveiller M. Active and alpha-1 proteinase inhibitor complexed leukocyte elastase levels in crevicular fluid from patients with periodontal diseases. *J Periodontol* 1997; 68: 256-261.
30. Mutlu, S, Richards A, Maddison P, Scully C. Gingival and periodontal health in systemic lupus erythematosus. *Community Dent Oral Epidemiol* 1993; 21: 158-161.
31. Nagler RM, Lorber M, Ben-Arieh Y, Laufer D, Pollack S. Generalized periodontal involvement in a young patient with systemic lupus erythematosus. *Lupus* 1999; 8: 770-772.
32. Orozco A, Gemmell E, Bickel M, Seymour GJ. Interleukin-1, interleukin-12 and interleukin-18 levels in gingival fluid and serum of patients with gingivitis and periodontitis. *Oral Microbiol Immunol* 2006; 21: 256-260.
33. Overall CM, Sodek J. Initial characterization of a neutral metalloproteinase, active on native 3/4-collagen fragments, synthesized by ROS 17/2.8 osteoblastic cells, periodontal fibroblasts, and identified in gingival crevicular fluid. *J Dent Res* 1987; 66: 1271-1282.
34. Page R, Offenbacher S, Schroeder HE, Seymore GJ, Kornman KS. Advances in the pathogenesis of periodontitis: summary of developments, clinical implications and future directions. *Periodontol* 2000 1997; 14: 216-248.
35. Salonen JI, Paunio KU. An intracrevicular washing method for collection of crevicular contents. *Scand J Dent Res* 1991; 99: 406-412.
36. Stichweh D, Arce, E, Pascual V. Update on pediatric systemic lupus erythematosus. *Curr Opin Rheumatol* 2004; 16: 577-587.

37. Tanaka M, Harigai M, Kawaguchi Y, Ohta S, Sugjura T, Takagi K, Ohsako-Higami S, Fukasawa C, Hara M, Kamatani N et al. Mature form of interleukin 18 is expressed in rheumatoid arthritis synovial tissue and contributes to interferon-gamma production by synovial T cells. *J Rheumatol* 2001; 28: 1779-1787.
38. Tso T K, Huang WN, Huang HY, Chang CK. Elevation of plasma interleukin-18 concentration is associated with insulin levels in patients with systemic lupus erythematosus. *Lupus* 2006; 15: 207-212.
39. Vogel RI. Periodontal disease associated with amegakaryocytic thrombocytopenia in systemic lupus erythematosus. *J Periodontol* 1981; 152: 20-23.
40. Wozniacka A, Lesiak A, Narbutt J, McCauliffe DP, Sysa-Jedrzejowska A. Chloroquine treatment influences proinflammatory cytokine levels in systemic lupus erythematosus patients. *Lupus* 2006; 15: 268-275.
41. Wyman TH, Dinarello CA, Banerjee A., Gamboni-Robertson, F, Hiester AA., England, KM, Kelher M, Silliman CC et al. Physiological levels of interleukin-18 stimulate multiple neutrophil functions through p38 MAP kinase activation. *J Leukoc Biol* 2002; 72: 401-409.